EnterNext welcomes OSE Pharma on Euronext in Paris

Dominique Costantini, co-founder et CEO of OSE Pharma, rings the closing bell.

OSE Pharma is a biotechnology group that specializes in the research and development of therapeutic products for the treatment of cancers and lung disease.
At the end of 2013, the group had a portfolio of 5 products in development phase, including 4 in phase II (colon, breast and ovarian cancer, and cystic fibrosis) and 1 in phase III (lung cancer).